Eisai Could Have Difficulty Ending Market Deal With Pfizer
This article was originally published in PharmAsia News
Executive Summary
Eisai's attempt to extricate itself from a marketing agreement with U.S.-based Pfizer for Eisai's Aricept (donepezil) for treating Alzheimer's disease may not be as easy as it thought. Eisai sought to end the deal after Pfizer announced it would take over another U.S. firm, Wyeth, but Pfizer is resisting the breakup. Eisai contends the merger with Wyeth violates Pfizer's contract with Eisai, so the contract has been nullified. At stake are huge sales commissions Eisai pays to Pfizer to market Eisai's best-selling drug. Eisai says it can do the marketing itself. (Click here for more - a subscription may be required
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.